Nippon Kayaku Co (4272) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
13 May, 2026Executive summary
FY2025 net sales reached ¥241.9 billion, up 8.7% year-over-year, with all major business units outperforming and profit attributable to owners rising 40.7% to ¥24.6 billion, mainly due to gains on investment security sales and strong segment performance.
Operating income increased 10.1% to ¥22.5 billion, and ordinary income grew 14.4% to ¥25.5 billion, with ROE improving to 9.0%.
All business segments posted higher revenue; Fine Chemicals and Life Science achieved profit growth, while Mobility & Imaging profit declined due to raw material costs.
Financial highlights
Net sales: ¥241.9 billion (+8.7% YoY); Operating income: ¥22.5 billion (+10.1% YoY); Profit attributable to owners: ¥24.6 billion (+40.7% YoY); Ordinary income: ¥25.5 billion (+14.4% YoY).
Gross profit increased to ¥72.9 billion; comprehensive income reached ¥38.7 billion.
Cash flows from operating activities were ¥28.8 billion; cash and cash equivalents at year-end were ¥53.4 billion.
Total assets rose to ¥398.7 billion, net assets to ¥280.1 billion, and equity ratio at 70.0%.
Extraordinary income rose by ¥9.4 billion from investment security sales.
Outlook and guidance
FY2026 forecasts: Net sales ¥260.6 billion (+7.8% YoY), operating income ¥25.4 billion (+13.1% YoY), profit attributable to owners ¥22.3 billion (-9.5% YoY) due to lower extraordinary gains.
All segments expected to grow revenue and profit; Mobility & Imaging to benefit from increased auto production and price pass-through.
Dividend forecast for FY2026 and FY2027 is ¥66.00 per share.
Capital investments projected to rise by ¥11.0 billion in FY2026; R&D expenses to increase by ¥3.0 billion.
Latest events from Nippon Kayaku Co
- Profit attributable to owners of parent rose 30.1% on 4.0% sales growth, outlook steady.4272
Q3 20262 Feb 2026 - Net sales up 4.1% and profit nearly doubled on investment gains despite cost pressures.4272
Q2 202612 Nov 2025 - Strong sales and profit growth driven by Mobility & Imaging and Fine Chemicals; outlook revised up.4272
Q1 202519 Aug 2025 - Sharp profit growth and raised forecasts driven by Mobility & Imaging and Fine Chemicals.4272
Q3 202519 Aug 2025 - Sales and operating income surged, with upward guidance and major treasury stock buybacks.4272
Q2 202519 Aug 2025 - Record profit and strong segment growth; FY 2026 sees sales up, profit slightly down.4272
Q4 202519 Aug 2025 - Sales rose but profits fell amid higher costs and global risks; outlook remains cautious.4272
Q1 202619 Aug 2025